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ABSTRACT
Epstein-Barr virus (EBV) is associated with a spectrum of benign and
malignant lymphoproliferative disorders, including acute infectious
mononucleosis (1M), Burkitt' s lymphoma (BL) and immunosuppression-
associated B celllymphoproliferative disease (LPD). Immunosurveilance
mediated by virus-specific cytotoxic T lymphocytes is believed to protect
immunocompetent hosts from EBV-associated lymphoma and LPD. Due to the 
lack of an adequate animal model, however, the precise immunologic
mechanisms which provide this protection have not been directly demonstrated
In VlVO.
Human peripheral blood mononuclear cell-reconstituted CB.-17-scid/scid-
mice (hu-PBMC-SCID mice) develop EBV-positive LPD following intraperitoneal 
injection of PBMC from EBV-seropositive donors. The SC1D mouse disease
mirrors human EBV-associated LPD in morphology, presence of the EBV
genome, clonality, and patterns of expression of latent viral cellular
differentiation antigens. The hu-PBMC-SCID mouse provides a unique small
animal model of EBV+ LPD, and it was used in this study to examine the role of
CD8+ CTL in controllng LPD. Survival time increase significantly when EBV.,
specific cytotoxic T-cell lines (CTL) are adoptive transferred into hu--PBMC-SCID 
- -
mice, demonstrating suppression of LPD in vivo by a CTL-mediated virus-
specifc mechanism. Survival time also increases significantly with
administration of alloreactive CTL lines, suggesting that a non-virus-specific
mechanism also contributes to control of EBV-associated LPD by CTL.
NOD-SC1D mice reconstituted with PBMC from donors with latent EBV
infection develop EBV+ LPD with significantly less frequency than do C.B.17- 
SC1D mice reconstituted with PBMC from the same donors. Administration 
anti-CD8 mAb to these mice depletes human CD8+ cells and increases the
incidence of LPD to 100%, demonstrating that CD8+ T cells are neccessary for
protection from EBV-associated LPD. Adoptive transfer of human CD8+ T cells,
but not CD4 + T cells, prevents LPD in CD8-depleted NOD-SCID mice. In vivo
depletion of CD4 + T cells prevents engraftment of human T cells, and LPD does
not develop in most mice after CD4+ cell depletion. These studies are the first to
directly demonstrate both the protective role of CD8+ T cells and a requirement
for CD4 + T cells in EBV - associated LPD in an in vivo model.
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CHAPTER 1. INTRODUCTION
A. The Epstein-Barr virus (EBV)
1. Biology of EBV.
Epstein-Barr virus (EBV) was first detected in 1964 in cultured cells from
African Burkitt's lymphoma (16). It was subsequently detected in lymphoid
cell lines from patients with various malignancies, infectious mononucleosis,
and apparently healthy individuals (43). EBV is a human lymphotropic
herpesvirus which infects over 90% of the world population. It is the human
prototype virus for the genus Lymphocryptovirus which are a member of the
gamma herpesvirus family. A member of the Lymphocryptovirus genus is
endemic in each species of old world primates, but none are found in other
species (38).
. TheEBV genome has been completely sequenced (3); It consists of a 172
Kb double-stranded DNA, which is linear in virions but circularizes soon
after infection of cells. The genome contains certain features shared by all
lymphocryptoviruses, including 3Kb internal direct repeat (IR) sequences and
0.5 Kb terminal direct repeat sequences (TR) (38). The number of iterations of
each of these repeat sequences varies between virus isolates, but is usually
maintained through sequential passage. This is an important characteristic
that can be exploited to assist in determining the clonalityof EBV-carrying
lesions (see below).
The host cell range for EBV is largely limited to B lymphocytes and the
squamous epithelial cells of the oropharynx. Primary infection with EBV
begins in the oropharyngeal epitheliun, which is permissive for viral
replication (51, 80). B lymphocytes are subsequently infected, probably by
trafficking through the oropharynx (2). EBV infection of B lymphocytes is
usually latent
, although replication can be induced in vitro and may occur 
vivo under certain circumstances. In less developed cultures primary
infection typically occurs in the first year of life and is asymptomatic. When
infection is delayed until late childhood or early adulthood, as it often is in
the developed world, it can result in acute infectious mononucleosis (1M), a
benign, self-limiting disease which is marked by sore throat
lymphadenopathy and fatigue. In either case primary infection is followed by
lifelong, persistent infection.
EBV is maintained in the persistently-infected human host as a
productive infection of the oropharyngeal epithelium and a latent infection
of B cells (43). It is unclear what relationship exists between these two sites of 
infection. Persistence is thought to be maintained by a reservoir of latent
virus being fed to the site of replication, because variations in the virus that
would be generated during replication are not found in sequential isolates
from saliva of infected individuals over a period of years (41). Furthermore,
maintainence of latent infection in B cells does not appear to require
continual reinfection via the oropharynx; treatment with acyclovir, which
blocks viral replication in the oropharynx, does not affect the number of EBV-
carrying cells in the blood, and virus can be detected in throat washings soon
after treatment is stopped (98). It is difficult to reconcile the evidence for B
cells as the reservoir of latent virus with data that suggests that B cells turn
over rapidly, with as much as 1% of the total pool being renewed daily (41).
One possibilty is that EBV-infected B cells are spared from clearance by virus-
induced mechanisms, such as the upregulation of bcl- gene expression by
the EBV LMP-1latent protein (23). Induction of bcl- expression has been
shown to protectB cells from programmed cell death (apoptosis) (23).
Two remarkable biologic properties of the virus are its abilties to induce
activation and growth transformation of infected B lymphocytes. Activation
occurs following attachment of the EBV gp350/220 glycoprotein to its receptor
CD21, which is also the C3d complement receptor (CR2) (17). Synthesis ofB
cell activation molecules, such as CD23 and CD30, accompanies activation
and does not require expression of EBV latent gene products (85). EBV-
induced growth transformation, or immortalization, occurs in mature B cells
which have undergone Ig gene rearrangements (11). It occurs after B cell
activation and requires synthesis of EBV latent gene products.
Growth transformation causes cells to proliferate indefinitely in vitro
and permits the propagation of permanent B-Iymphoblastoid cell lines (B-
LCL) which carry the virus as a latent infection (38). These cell lines provide
an in vitro system in which to study EBV biology and virus-specific cellular
immunity, whereas cultivation of infected epithelial cells has proven to be
more difficult. EBV can also infect and immortalize lymphocytes from some
non-human primates. Cell lines established from the cotton-top tamarin 
produce high titers of virus; one of these, the B95.8 cell line, is used routinely
as a source of cultured virus (44). The immortalizing property of EBV also 
underlies the function of EBV in its associated lymphoproliferative diseases.
Much of the existing knowledge of the biology of EBV has been gathered
from the study of in vitro EBV-transformed B-LCL. Viral gene expression in
these latently infected cell lines is limited to the latent proteins: six nuclear
proteins, EBNAs 1-6, and three latentmeinbrane proteins, LMP- , LMP-
and LI\1P-2B (38). (The EBNA protein are sometimes referred to as EBNA-
, .
2, - C, and -LP.) This pattern of latent gene expression has been termed the
latency il program; latency programs I and II have been demonstrated in
other EBV-carrying cell lines and tumor biopsies (69). The latency I program
is expressed in primary BL cells and some BL cell lines, and permits
expression of only one of the latent proteins, EBNA-l. The latency 
program, found in vivo in Hodgkin s disease and nasopharyngeal carcinoma.
(NPC), and inducible in BL lines, permits expression of EBNA-1 plus the
LMPs. It is often assumed that the phenotype of infected cells in vivo 
identical to that of B-LCL, but recent evidence suggests that the latency II
- program may more accurately represent the phenotype of latently-infected B
cells in vivo, which have a non-activated (ie: CD23-) phenotype (45). EBNA-'2
induces the expression of CD23 in B-LCL (96); since EBNA-2 is not expressed
in the latency II program, it would be expected to lead to the CD23- phenotype.
2. Diseases associated with EBV.
EBV has been associated with malignancy since its initial detection in
Burkitt' s lymphoma (BL) cells (16). It has since been associated with a variety
of benign and malignant lymphoproliferative disorders of B lymphocyte and
epithelial cell origin, including 1M, oral hairy leukoplakia, nasopharyngeal
carcinoma (NPC), and B celllymphoproliferative diseases in
immunodeficient hosts (2). More recently EBV has also been detected in T
cell lymphomas (13), Hodgkin s lymphoma (19) and several tumors of non-
lymphoid and non-epithelial cell origin (37, 42).
EBV is consistently found in association with two types of B lymphocyte
tumors: endemic BL and immunoblastic lymphoproliferative disease (LPD)
occurring in immunocompromised patients. In BL, host immune control of
EBV infection is believed to be suppressed by pre-existing malaria; the
sporadic form of BL, which occurs in areas where malaria is not endemic, is
usually negative for EBV. Patients susceptible to EBV-associated LPD include
those with congenital immunodeficiency diseases, recipients of allogeneic
organ transplants receiving immunosuppressive therapy and patients with
AIDS (5, 21 , 55, 56, 71 , 81).
Several characteristics distinguish BL from EBV-associated LPD: BL is
monoclonal; BL cells express CD10 (CALLA), an antigen found on immature
. B cells and certain leukemias and do not express CD23 or the EBV latent
proteins, with the exception of EBNA-1; expression of MHC antigens and
many adhesion molecules is very low to absent. Finally, BL cells always carry
a chromosomal translocation involving c-myc. Many of these features appear
to allow BL to elude host immunosurveilance mechanisms. In contrast
EBV-associated LPD is usually, but not always, oligo- or polyclonal, and it
expresses cell surface and latent viral antigens in a pattern that is very similar
to B-LCL. C-myc translocations are not found in LPD. BL is also easily
distinguished from LPD by its distinctive morphology:
3. Immune responses toEBV.
a. The immune reponse. in acute infectious mononucleosis. The cellular
immune response to primary EBV infection during acute 1M is dominated by
a highly activated and expanded population of "atypical" lymphocytes (76).
These cells are primarily of the CD3+ /CD8+ cytotoxic/suppressor T cell
phenotype and are unusual in their apparent lack of specificity for virus and
restriction by host MHC antigens (75, 90). Rigorous analysis of T cell
subpopulations in acute 1M PBMC has revealed. the presence of distinct
alloreactive and EBV-specific components (87). Cytotoxic T cell (CTL)
responses to other human viruses such as cytomegalovirus (61), measles (36),
mumps (35), and influenza (91), are typically MHC-restricted and virus
specific. Generation of virus-specific CTL is only one of several potential
cellular immune responses to these infections; the importance of CTL in
protecting the host from disease is not clear in every case. For example, in
acute measles virus infection, NK cells represent a major component of the
cytotoxic response (33).
b. The immune response in latent infection. In vitro stimulation of
peripheral blood mononuclear cells (PBMC) from latently-infected (ie: .EBV-
seropositive) individuals with autologous EBV-transformed B-
lymphoblastoid cell lines (B-LCL) usually results in the induction of EBV-
specific, MHC class I-restricted CTL. This in vitro stimulation procedure.
demonstrates the presence of memory CTL in latently infected individuals.
By using vaccinia recombinants which express individual latent genes 
target cells, several EBV latent gene products have been identified as target
antigens for in vitro- stimulated EBV-specific CTL (66). The most frequent
responses have been mapped to the EBNA 3 family of proteins, with others
identified against EBNA- , LMP- l and LMP-2; no CTL responses to EBNA-1 .
have been identified so far. The dominance of particular antigens in the-
response made by individuals is often correlated with expression of certain
HLA alleles; for example, the MHC class I allele HLA B8 frequently presents
an epitope of EBNA-3A.
. Although the EBV -specific CTL responses just described are generally
believed to protect the host against EBV-associated LPD, their role has been
difficult to assess directly due to the lack of an adequate animal model. The
cotton-top tamarin, or marmoset, is the only primate species known to
reliably produce LPD on exposure to EBV (77); however, the fact that it is a
protected species severely limits 
-its use as an experimental model. 
. ,
B. The severe combined immunodeficient (SCID) mouse.
1. The scid/scid mutation.
The scid mutation in mice was described by Bosma in 1983 (6). The
. mutation arose spontaneously in the C.B. 17lcr inbred strain, which is an
immunoglobulin congenic partner of BALB/c. The mutation gave rise to a
severe combined immunodeficiency (SCID) syndrome with many of the
features of human SCID, though for different reasons, as was later discovered.
A C.B.- 17 strain homozygous for scid (C.B. 17 scid/scid) was established by
selective breeding; the mutation segregated asa single autosomal recessive
gene which has since been mapped to the centromeric end of chromosome 
(7).
2. The SCID mouse phenotype.
B.- 17 scid/scid mice, or SCID mice, fail to generate T and B lymphocyte
antigen receptors, apparently because of a defect in double-stranded DNA
repair (24). As a result, they are severely deficient in humoral and cell-
mediated immunity. SCID mice are unresponsive to T cell-dependent and T
cell-independent antigens, and their spleen cells fail to proliferate in mixed
lymphocyte culture or in response to mitogens. They accept allogeneic skin.
grafts, and as Mosier first described in 1988, they also accept grafts of human
peripheral blood mononuclear cells (PBMC) (47).
C. The hu-PBMC-SCID mouse.
1. Engraftment of human PBMC in SCID mice.
Reconstitution of SCID mice with human PBMC was accomplished by
Mosiet, et al. by injecting the cells into the peritoneal cavity (47). The
majority of "reconstituted" mice, or hu-PBMC-SCID mice, spontaneously.
produced human immunoglobulin (Hulg) after receiving 2xl07 or more cells.
Transfer of a critical number of cells was found to be required for detectable
levels of Hulg to be made, for reasons that are unclear. One possibilty is that
.. a large number of cells is needed to overcome resistance to engraftent by
intact components of the murine immune system, ie: many of the transferred
cells do not survive for long in the murine host. Varying degrees of low
level graft versus host disease (GVHD) have been reported (30, 34), but
generally it does not appear to pose a significant problem.
Studies of the distribution and phenotype of human cells persisting in
hu-PBMC-SCID mice have yielded wildly variable results (29 40, 84). The
predominant cell type has consistently been identified as single positive T
cells; most groups report detecting fairly low percentages of these cells (.:10%)
outside of the peritoneal cavity(30, 84). The majority of T cells recovered
from lymphoid organs two weeks or more after engraftment express the
. CD45RO+, or memory cell, phenotype (88). Most of these cells also express
MHC class II (DR) antigens, which is indicative of an activated phenotype (29).
Primary and secondary humoral and cellular immune responses to everal
antigens have been demonstrated in the hu-PBMC-SCID mouse, but are
mostly very weak (39 , 74, 79, 88).
The hu-PBMC-SCID mouse has been used extensively to study the
pathogenesis of human infectious and autoimmune diseases (34 48, 72, 88,
92). It also provides a small animal model in which to study mechanisms of
T cell control of EBV-associated LPD.
2. EBV-associated LPD in hu-PBMC-SCID mice.
Reconstitution of SCrD mice with 50x106 or more PBMC from EBV-
seropositive donors has been found to lead to the development of B cell
lymphomas of human origin (46, 47). The initial report of this phenomenon
suggested that these tumors resembled BL(47), but this was not borne out in
subsequent studies. Several groups have since reported that these
lymphomas are always positive for the EBV genome, are usually oligo clonal
and express a pattern of latent viral and cell surface antigens that mirrors
those found on B-LCL (12). (49 58). Tumor morphology has been
repeatedly reported to be immunoblastic rather than BL-like. These findings
have made it clear that the tumors which arise in hu-PBMC-SCID are 
remar kably similar to EBV -associated LPD arising. in. immunocompromised
human hosts, and are not in most cases related to BL
3. The NOD /LtSz-scid/scid mouse.
The apparently low level of human cell engraftment in hu-PBMC-SCID
mice has prompted efforts to improve the model. Treatment of mice with
irradiation or anti-asialo GMI antibody before reconstitution to deplete NK 
cell activity has been partially successful in improving engraftment (11). This
finding suggests that host inate immunity influences human cell
engraftment, and led to an examination of the effect of host background strain
on engraftment in mice with the scid mutation (20, 28).
The NOD/Lt inbred mouse strain is deficient in NK cell, macrophage,
and complement activities (78); this strain was used as genetic stock onto
which the scid mutation was backcrossed to create the NOD /LtSz-scid/scid
mouse (hereafter referred to as NOD-SCID) (78). NOD-SCID mice lackT and B
lymphocyte function and have the defects in inate immunity which
accompany the NOD/Lt background strain (Table 1). In a comparison of four
inbred mouse strains homozygous for the 
scid mutation, the highest level of
PBMC engraftment were seen in the NOD-SCID strain (28). The majority of
engrafted cells were found to have a CD3+ (T cell) phenotype. The NOD-SCID
mouse therefore provides an improved model for studies of T cell function
in human diseases.
D. Objectives of the study.
The primary objectives of the study which constitutes this thesis were 
to determine the degree to which the tumors arising in hu-PBMC-SCID mice
resembled either BL or immunosupression-induced LPD and 2) to
demonstrate whether or not EBV-specific CTL could prevent EBV-associated
LPDin the hu-PBMC-SCID mouse. The first objective was achieved by others
and published during the course of the project. My results and conclusions
are consistent with those published and are included here.
The results of experiments addressing the second objective were not
definitive, and led to additional studies using the PBMC-reconstituted NOD-
SCID mouse. The objectives of these experiments were: 3) to determine
whether reconstituted NOD-:SCID mice were susceptible to EBV-expressing
LPD; and 4) to determine the role of CD8+ human T cells in preventing LPD 
in this model. In the process of addressing these objectives, an important role
for CD4+ T cells in the NOD-SCID model was discovered.
Table 1. Immunologic defects in NOD /LtSz-SCID mice.
Imff une function:
Mature Band T
lymphocytes
NK cell function
APCl
Serum C' activity
Reconstitution of spleen
with human
. T cells
Spontaneous IDDM
CB. 17-SCID
Mouse strain:
NOD ILtSz-
SCID
NOD /Lt
yes
low
endogenous
and induced)
decreased
absent
yes
lAntigen presenting cell (APC) function was assessed LPS-stimulated IL-
secretion by BM-derived macrophages.
2 Insulin-dependent diabetes melltus (IDDM) in NOD /Lt mice is T cell
dependent and T cell mediated.
normal/high low
endogenous
and induced)
decreasednormal
normal/high absent
low high
(-:10% of spleen (::25% of spleencells) cells)
CHAPTER II. MATERIALS AND METHODS
A. SCID mice
17-scid/scid (C.B. 17-SCID) and NOD/LtSz-scid/scid (NOD-SCID) mice
were bred in the University of Massachusetts Medical Center breeding colony,
which is maintained under specific-pathogen free (SPF) conditions. C.B.
SCID breeding. pairs used to establish the colony were provided by Dr. Donald
Mosier and the Medical Biology Institute, La Jolla, CA. NOD-SCID breeding
pairs were provided by Dr. Leonard Shultz, the Jackson Laboratory, Bar Harbor
ME. Mice were 6-12 weeks old when used in experiments. Age matched mice
of either sex were used. Experimental animals were maintained under SPF
conditions.
B. PBMC donors.
PBMC were obtained from healthy, EBV-seropositivevolunteer donors as
by-products of plateletpheresis (Model 30, Haemonetics, Inc. Braintree, MA) in
. the University of Massachusetts Hospital blood donor room or as heparinized
blood by standard venipuncture. Heparinized blood from acute 1M patients.
was obtained from the Student Health Services at the. University of
Massachusetts, Amherst. All patients had clinical and laboratory evidence of
acute 1M, with fever, sore throat, lymphocytosis, splenomegaly and at least 20%
atypical lymphocytes on a differential white blood cell count. All patients were
positive for heterophile antibody by the Monospot test. Acute 1M blood was 
obtained within five days of the first positive Monospot test and within ten
days of the onset of symptoms. Written informed consent was obtained from
each patient before entry into the study.
C. Isolation of donor lymphocytes.
PBMC from pheresis of peripheral blood were isolated under sterile
conditions by density gradient centrifugation using Ficoll-Hypaque (Pharmacia
LKB Biotechnology, Inc., Piscataway, NJ). Cells were recovered from the
interface and washed twice with phosphate-buffered saline (PBS). The cells
were then examined for viabilty by trypan blue dye exclusion and the
lymphocytes enumerated. PBMC that were to be injected into SCID mice were
suspended in PBS at a concentration of 1x108 / ml. Blood from acute 1M patients
was diluted in RPMI1640 medium supplemented with 20U / ml human
recombinant IL-2 and incubated at 37 C overnight. PBMC were isolated from
the acute 1M blood the next morning according to the described protocol.
D. Reconstitution of SCID mice.
C.B.17-SCID or NOD-SCID mice were injected intraperitoneally (Lp.) with 5-
6x107 PBMC within 2 hr of isolation. From 2 to 13 mice (mean = 5 mice) were
reconstituted with each acute 1M donor, and from 2 to 32 mice (mean=15 mice)
were reconstituted with each latently-infected PBMC donor. PBMC from some
donors were used to reconstitute mice in multiple experiments whereas other
donors were used only once. Biood was collected from the tail vein two to six
weeks after the PBMC injection and by cardiac puncture at the time of terminal
sacrifice; and assayed for the presence of human immunoglobulin (HuIg) by
one of the methods described below. Mice with serum HuIg levels of at least 1
ug/J.l were considered to be successfully reconstituted. Individual mice were
excluded from the analyses if: (1) serum Hulg was.: LOp,g/lll (37/240 C.B.17-
SCID mice), or (2) the mouse was not examined or could not be evaluated
immediately after its death. In addition, 10% of mice that were not tested for
Hulg and did not develop LPD were excluded (one mouse); this represents the
proportion of mice predicted to be negative for HuIg. Only 1/116 C. 17-SCID
mice which developed LPD and were tested for HuIg was negative for HuIg
(0.86%).
E. Immunoglobulin assays.
1. Murine immunoglobulin.
Mice were bled from the tail vein before being used in reconstitution
experiments, and the serum was tested for levels of murine immunoglobulin
(Mulg) using a commercial semi-quantitative, filter-based enzyme-linked
immunoassay kit (Mouse Ab-Stat, Sang-Stat Medical Corp, Menlo Park, CA).
The assay was scored as: negative = 0-lug/ml, + /- = 1-5 ug/ml, 1+ = 5-10 ug/ml,
2+ = 10-50 ug/ml, 3+ or 4+ = ::50 ug/ml. Mice with greater than 1 ug/ml of
Mulg were considered to be "leaky" (8) and were not used in reconstitution
experiments.
,..
2. Human immunoglobulin.
Two methods were used to measure human immunoglQbulin levels in post-
reconstitution SCID mouse sera. For testing of the C.B.17-SCID mice, a semi-
quantitative immunoassay similar to the mouse Ig test was used (Human Ab-
Stat, Sang-Stat Medical Corp, Menlo Park, CA). When this kit later became
unavailable, an in-house quantitative competetive ELISA was used to test most
of the NOD /LtSz-SCID sera (32) Briefly, assay plates (Nunc microwell) were
coated with 50ml of human gamma globulin (Cappel) at O.25mg/ml in PBS
containing 0;05% sodium azide for 2 hr at 37 C, washed with ddH20 and
blocked for 30 min. at room temperature with borate-buffered saline containing
05% Tween 20 and 0.25% bovine serum albumin. HuIg standard (Cappel) was
serially diluted 1:3 to create a range of 0.4 mg/ ml to 100 mg/ ml. . Test samples,
controls and standards (30-50 ml) were mixed 1:1 with 2x alkaline phosphatase-.
conjugated goat anti-human Ig antibody (1:5000 dil. ) in a 96-well PVC assay
plate and incubated for 30 rhino at RT. Fifty ml of the sample plus conjugate
mixture was added to the Ag-coated plates and incubated 2 hr at room T. Plates.
were washed 3 times with ddH20 and 75ul of 3 mM NPP substrate was added
(Bio-Rad). Plates were read at 405 nm on a micro titer plate reader after 1 hr.
Hulg concentrations were calculated by construction of a standard curve.
F. Termination of experiments.
1. Tissue harvest.
At scheduled timepoints or when moribund, reconstituted mice were
anesthetized with ketamine-"rompun, bled by cardiac puncture andeuthanized
by cervical dislocation. Autopsies were performed to confirm the presence of
LPD, and tumor tissue was excised and preserved in 10% neutral buffered
formalin (NBF) and/or by quick freezing in liquid nitrogen. To assess human
PBMC engraftment and in vivo depletion, peritoneal cells were collected by
open lavage with 5-6 ml PBS, and spleens were harvested. Cells recovered 
lavage and spleen cells were analyzed for human lymphocyte surface markers
by flow cytometry.
2. Histopathology.
Tissues were fixed in 10% NBF and processed for histopathology by
standard automated processing and paraffin embedding procedures. Sections
were cut at 5-6m thickness and stained with hematoxylin-eosin ' for microscopic
examination. Additional slides were cut from some tumor tissue for standard
immunohistochemistry and stained with immunoperoxidase-conjugated anti-
CD45 monoclonal antibody (this procedure was performed in the laboratory of
Dr. Leonard Shultz, the Jackson Laboratory, Bar Harbor, ME).
G. DNA Analysis.
1. Isolation of tumor DNA.
Genomic DNA was isolated from quick-frozen tumor tissue using a
modification of a previously described method (67). The frozen tissue was
homogenized to a cell suspension in buffer containing 10 mM Tris, 10 mM
EDTA and 100 mM NaCI using a tissue homogenizer, followed by the addition
of an equal volume of buffer containing O.4mg/ml' proteinase K and 1% SDS,
and was incubated for 1 hour at 37 c. Cellular DNA was purified by three
25:24:1 phenol/chloroform/isoamyl alcohol extractions and ethanol
precipitation followed by micro-centifugation.
2. Southern blotting.
DNA samples were digested with restriction endonucleases and buffers
obtained from Strata gene (LaJolla CA). DNA was digested with BamHI for
hybridization with the EBV-BamW and BamNJ probes, or with HindIII for
detection of Ig JH gene rearrangements. Restriction digests were separated on
75% agarose gels at 1.0 V / cm in Tris-acetate buffer (40 mM Tris-acetate, 1 mM
EDTA) for 16-18 hours. For the JH analysis, the gels was denatured, neutralized
and blotted onto nylon membranes according to the manufacturer s protocols
(Oncor, Inc. , Gaithersburg,MD). The immobilzed DNA was preincubated in a
50% formamide prehybrization solution (Hybrisol I, Oncor, Inc.). Analysis of
the EBV genome was according to standard Southern blot methods (73). All
probes were labeled with 32p-dCTP by the random primer method (random
primer labeling kit, Bio-Rad Laboratories, Richmond, CA), and washed
according to standard or product (Oncor) protocols.
3. Probes.
The Ig JH probe used to detect rearrangments of Ig heavy chain J region
genes is a commercially-available 5.6 kB BamHI-HindIII fragment of the
human immunoglobulin JH gene (Oncor Inc.) (63). The EBV-BamW probe is a
1 kb BamHI fragment from the EBV internal repeat (Bam W) in pBR322 (a 
. gift from E. Kieff) (25). The BamNJ probe, used to distinguish circular and
linear episomal forms of the EBV genome and to corroborate tumor clonality,
is an 8.4kb BamHI fragment .containing the terminal repeats inserted into
pUC18 (62 95).
H. Flow cytometry.
Single cell suspensions of tumor cells were prepared by teasing apart fresh
tumor tissue with two scalpel blades in PBS or RPMI 1640 medium. Spleen cells
were prepared by dissociation between the frosted ends of 2 glass microscope
slides and passage through a tissue strainer (Falcon Cell Strainer, Becton
Dickinson Labware, Lincoln park, NJ). Red blood cells were lysed witb a
hypotonic ammonium chloride solution. The remaining nucleated cells were
washed in PBS, examined for viabilty by trypan blue dye exclusion and
lymphocytes counted. The cells were then stained. with fluorescein (FITC)- or
phycoerythrin (PE)-labeled monoclonal antibodies (mAbs.) according to the
. manufacturer s ihstructions, either immediately or after several weeks in
culture. MAbs which recognize CD45 (anti-HLe-1), CD3 (anti-Leu 4), CD4 (anti-
Leu-3a), CD8 (anti-Leu-2a), CD19 (anti-Leu-12), CD20 (anti-Leu-16), CD23 (anti-
Leu-20), and CD10 (anti-CALLA, common acute lymphoblastic leukemia
antigen) (Becton-Dickinson, San Jose, CA) were used for direct
immunofluorescent staining, and unlabelled anti CD30 (anti-Ki- , DAKO
Corp., Carpinteria, CA) and FITC-labelled goat anti-mouse Ig (Coulter
Immunology, Hialeah, FL) were used for indirect staining. Cell surface
phenotypes were determined by flow cytometric analysis using a F ACScan
instrument (Becton-Dickinson).
1. Cell lines.
1. B-lymphoblastoid cell lines.
lymphoblastoid cell lines were initiated from donor PBMC by induction
with supernatant from the- EBV-' producing cell line B95.8 (50). PBMC were
cultured at a concentration of 2x1-o6/ml in 48-well tissue culture plates.
Culture medium was RPMI 1640 medium supplemented with 15% fetal bovine
serum (FBS) (RPMI/15%), 10% B95. 8 supernatant and 2 ug/ml cyclosporin A;
the cultures were fed twice weekly with RPMI/15%, and observed for clusters of
proliferating cells. After approximately 3-4 weeks in culture, the B-LCL were
usually well established and were transferred to 25 cm2 tissue culture flasks and
maintained at a concentration of 4-8x105 cells/ml. B95.8 supernatant was
produced by seeding B95.8 cells at a concentration of 4x105 ml and culturing
for ten days in RPMI/15% without feeding, and harvesting the supernatant.
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The supernatant was centrifuged in 50 ml polypropylene centrifuge tubes at
1000xg for 20 minutes three times to remove cellular contamination, and
frozen in aliquots at -
2. Cytotoxic T lymphocyte lines.
All CTL lines were initiated with PBMC which had been depleted of NK
cells by incubating with anti-CD16 mAb (Leu llb, Becton Dickinson) for 30 min,
on ice, washing once with PBS, and incubating for 45-60 min.- at 379C with
rabbit complement (Cedarlane Laboratories, Hornsby, Ontario) diluted 1:3-1:5
with RPMI.
a. Generation of EBV -specific CTL. EBV -specific cytotoxic T cell lines
were generated by culturing NK cell depleted PBMC with mitomycin c-treated
autologous B-LCL at a ratio of 40:1 in RPMI/15%, in 24-well tissue culture.
plates. Cultures were restimulated weekly with autologous B-LCL, at a
responder to stimulator ratio of 5:1 , and were fed with 1/2 volume fresh.
medium twice weekly. Beginning at day 10 and thereafter, the medium was
supplemented with 20U/ml recombinant human interleukin-2 (rhIL-
Boehringer Ingelheim). Celllines were tested for surface phenotype and
cytotoxic activity after 3-4 weeks in culture.
b. Generation of alloreactive CTL. MHC class I allol"eactive cytotoxic T 
cell lines were generated by culturing NK cell-depleted PBMC with' mitomycin
treated allogeneic B-LCL at a ratio of 40:1 in RPMI/15%, in 24-well tissue
culture plates. Cultures were restimulated weekly at a responder to stimulator
ratio of 5:1 with allogeneic B-LCL and fed twice weekly. Beginning at day 10
and thereafter, the medium was supplemented with 20U /ml rhIL"-2. Cell lines
were tested for surface phenotype and cytotoxic activity after 3-4 weeks in
culture. Allogeneic stimulator cells were always mismatched for all identified
class I alleles, to avoid the possibilty of stimulating an EBV -specific cytotoxic 
response which was restricted to an allele shared by the responder and the
stimulator. Tissue tying of cell lines was performed by the University of
Massachusetts Hospital HLA laboratory.
J. Cytotoxicity assay.
The cytotoxic activity of the CTL lines against various target cells was
determined in standard 51 Chromium-release assays performed immediately
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prior to injection into mice. Target cells were autologous B-LCL, HLA class 
i;;f,
; mismatched B-LCL or single cell suspension of tumor cells from a hu-PBMC-
SCID mouse. Tumor cells originated from the PBMC of the same individual
from whom the CTL were generated. Target cells were incubated with 100
inCi/106 cells of Cr (as sodium chromate; DuPont-NEN) for 1 hr at 37
washed three times and suspended at a concentration of 1x105 cells/ml in
RPMI/15%.
l.Target cells.
Target cells (100ml) were added to wells of 96-well culture plates. The
concentration ofCTL was adjusted to 2x106/ , and appropriate dilutions
made to achieve the effector to target ratios used in the assay. The diluted CTL
were added to wells in 100ml volume. The plates were centrifuged for 3 min.
at 500xg and incubated for 4 hr at 37 C, after which 100ml of supernatant was
harvested and couhted in a gamma counter. Maximum 5 Cr release was
determined by counting 50ml of labeled target cell suspension. Spontaneous
SlCr release was determined by incubating target cells with culture medium
; alone. Percent specific lysis was calculated as: 100 x (experimental cpm -
, spontaneous release cpm)/ (maximum release cpm - spontaneous release cpm).
, CA-Cricket Graph III software (version 1.5.2; Computer Associates
. International, In , Islandia, NY) was used to plot % specific lysis for Figures 8-
10.
2. Calculation of lytic units.
. Relative cytolytic activity of the CTL lines was determined by calculating
lytic units (L.U.) as previously described (97). Percent specific lysis values were
plotted versus the log of the effector cell number. A lysis value of 50% was
used to determine the number of lytic units per 106 effector cells. CA-Cricket
Graph ill software was used to generate L.U. plots.
K. Adoptive transfer of CTL lines.
The number of CTL injected for each twice-weekly treatment was
(letermined by the calculated number of L.U. per 106 cells. Each CTL injection
:contained approximately 100-200 L.U. of activity against either autologous B-
i,tCL (for EBV-specific CTL) or allogeneic B-LCL (for alloreactive CTL). CTL were
washed and suspended in an appropriate voluffeof PBS for each mouse to be 
injected with 0.25- 5 ml volume.
Production and administration of monoclonal antibodies.
1. Hybridomas.
For in vivo depletion of human lymphocyte subsets, monoclonal
antibodies were produced as ascites in the peritoneal cavity of C.B.-17 scid mice.
The OKT4 (CRL 8002) hybridoma secretes an IgG2b anti-CD4 mAb, and the
. OKT8 hybridoma (CRL 8014) secretes an IgG2a anti-CD8 mAb;both were
purchased from the American Type Culture Collection (ATCC). The B73.
hybridoma secretes an IgG1 anti-CD16 antibody, and was a gift from Dr. Giorgio
Trinchieri of The Wistar Institute (Philadelphia, P A) The S- l hybridoma
secretes an IgG2a anti-SRBC mAb (used as a control), and was also purchased
from ATCC (#TIB111). Hybridoma cells were expanded in tissue ctiltureflasks
in the medium specified by the supplier. In general, medium was
supplemented with b-mercaptoethanol and sodium pyruvate in addition to the
routine growth medium supplements. Cells were maintained at a density of 1-
2x105/ , fed with fresh medium, and expanded until numbers were sufficient
to inject into mice for ascites production.
2. Production of ascites.
Hybridoma cells were harvested while in log phase growth, washed with
PBS, and injected i.p. into C.B.17-SCID mice which had been primed with O.5ml
of pristane 10 days earlier. Between 0.5 and 5x106 cells were injected into each
animal. After 10-14 days, when the mice exhibited signs of ascites 
accumulation, the ascites was tapped with a 20-22 gaugeVacutainer needle into
sterile test tubes. Ascites was tapped over several days and those containing
the same Ab were pooled. Mice were sacrificed by cervical dislocation.
3. Antibody purification and administration.
MAb was purified from pooled ascites by caprylic acid precipitation of non-
Ig proteins followed by ammonium sulfate precipitation of Ig. Precipitated Ig
was dissolved in PBS and dialyzed against PBS to remove residual salts. 
sample of the purified Ab was analyzed by SDS-P AGE to determine the degree
of purity. All Ab preparations were at least 90% pure Ig. Concentration was
determined spectrophotometrically. Abs were filter sterilzed before injecting
0.5 mg i.p. into reconstituted SCID mice.
4. In vivo depletion.
To deplete subsets of human lymphocytes in vivo SCID mice of either
strain were injected with OKT4, OKT8 or B73.1 mAbs 0 to 3 days after after
PBMC reconstitution. In one experiment, Ab was injected six weeks after
PBMC reconstitution (Fig. 12). In some depletion experiments, control mice
were injected with the IgG2a control mAb S-
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M. Isolation and adoptive transfer of T cell subsets.
Purified populations of T cells were obtained by immunomagnetic
isolation using mAb-coated beads (Dynabeads M-450, Dynal A. , Oslo
Norway). PBMC were positively selected for CD4+ or CD8+ cells with the Ab-
coated beads according to the manufacturer s instructions, and the cells
detached from beads using the Detach-a-bead reagent (Dynal).. The resulting
populations were greater than 95% pure CD4 + and CD8+ cells when assessed by
, flow cytometry.
N. Statistical analyses.
Kaplan-Meier estimates of cumulative survival and logrank (Mantel-Cox)
comparison were calculated using Statview and Survival Tools for StatView
software (Abacus Concepts, Inc., Berkley, CA). P-values for significance of
tumor frequency was calculated by Chi-square analysis; also using StatView.
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CHAPTER III. RESULTS
A. Experiments in C.B.17-SCID mice.
1. Immune recoI;stitution of C.B.17-SCID mice with peripheral blood
mononuclear cells from individuals with acute or latent Epstein-Barr virus
infection.
Immlme reconstitution of C.B.17-SCID mice consisted of intraperitoneal
injection of 5x107 human PB1tIC. The PBMC donors belonged to one of the
following groups: (1) individuals with serological evidence of past EBV
infection (17 donors; these wil be referred to as latently infected), or (2) patients
in the acute phase of infectious mononucleosis (32 donors; eferred to as
acutely infected or 1M). PBMC from the acutely infected donors contain higher
percentages of activated CD8 T lymphocytes and a 10- to 1000-fold higher
percentage of EBV-infected B lymphocytes than PBMC from latently infected
individuals (45, 89, 99). Several potential indicators ,?f human PBMC
engraftment were investigated, including measurements of human cell
numbers in peripheral blood, peritoneal wash and spleen, an9. human
immunoglobulin in serum. Flow cytometric analysis four to eight weeks after
reconstitution revealed significant numbers (:?5%) of human cells consistantly
present only in the peritoneal cavity (data not shown). Occasionally, larger
numbers of human cells were recovered from spleens.
a. Production 0f human immunoglobulin. Injection of C.B.17-SCID mice
with human PBMC resulted in the sp mtaneous secretion of human
immunoglobulin (Hulg), which could be detected in the serum by two weeks
(Fig. 1). Mice with Hulg levels of 1 J.g/J.I or higher were considered, to be
successfully reconstituted. Successful reconstitution occurred in 90% of mice
injected with PBMC from latently-infected donors and 75% of mice injected
with PBMC from acutely-infected donors. 
b. Incidence of lymphoproliferative disease. LPD of human B cell origin
developed in 216 of 314 PBMC-reconstituted SCID. mice (Table 2). . Lesions
consisted of single or multiple-site tumors of lymphoid organs, liver, lung,
heart and/ or muscle. The incidence of LPD was similar (p=0.29) in mice
reconstituted with PBMC from acutely infected or latently infected donors. The
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average time from reconstitution to the development of LPD was 11.5 weeks
for both groups. Mice which developed LPD made higher levels of HuIg than
mice which did not develop LPD (Fig. 1); this was presumably due to Ig
secretion by the tumor cells.
PBMC donors varied considerably in their abilty to generate LPD in SCID
mice, with incidence of LPD ranging from 0% to 100% for individual donors
(Table 3). When a single donor was used in more than one experiment/the
incidence of LPD often varied between experiments. PBMC from donor B, for
example, generated LPD in 83% of mice in experiment 2 and in '0% of mice in
experiment 3; similar results were seen withPBMC from donor G. These
results are likely to reflect changes in the number of EBV -infected B
lymphocytes present in the circulation at the time PBMC were donated. All but
one of the 17 PBMC donors produced tumors in one or more experiments; the
donor which did not generate tumors was used in only one experiment. In.
experiments conducted by Dr. R. M. Hesselton, mice reconstituted with 50 x 106
P13MC (23 mice with two donors) or spleen cells (10 mice with one donor) from
EBV-seronegative donors did not develop LPD. Mice injected with 20 x.106 or
fewer cells from EBV-seropositive donors were also free of LPD (data not
shown).
c. Characterization of LPD in hu-PBMC-SCID mice. EBV appears to be
involved in the pathogenesis of two human B cell tumors. . These are Burkitt's
lymphoma (BL) and immunoblastic B cell lymphomas which arise as 
complication of immunosuppression. To determine whether the SCID mouse
tumors resembled one of these types of B cell tumors, cells from hu-PBMC-
, SCID mouse tumor masses were analyzed for surface antigen phenotype,
presence and clonality of the EBV genome, tumor cell clonality, and
histopathology.
. i. Expression of cell surface antigens. The pattern of surface antigen
expression on hu-PBMC-SCID mouse tumors were similar to those expressed
on B-Iymphoblastoid cells (Table 4A and B). However, the levels of expression
of antigens found on resting B cells (CD19 and CD20) and of B cell activation
antigens (CD23 and CD30) were less intense on the tumor cells than would be
expected on B-LCL (Table 4B). The absence of CD10 expression is significant
because CDlO (or CALLA) is strongly expressed on BL cells but not B-LCL (Table
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4A)(69). The SC1D mouse tumors are further distinguished from BL by their
strong expression of MHC class II antigens, which are weakly expressed in BL.
, ii. Presence of the EBV genome and replicating viral forms. The EBV
genome could be demonstrated in all of the SCID mouse tumors examined
using Southern blot analysis with the Bam W probe. Because it detects internal
repeat sequences (Fig. 2), this probe is highly sensitive for detection of the EBV
genome. A representative group of tU!Tors is shown in Figure 3, including
four originating from acute 1M PBMC (lanes 2, 3, 8 and 9) and five from
latently-infected PBMC (lanes 1 6 and 7).
TheEBV genome exists in two distinct forms: during latency it is circular
and when replicating and in complete virions it is linear. Circularization
occurs by the joining of tandem repeat sequences, or terminal repeats (TRs) at
each end of the linear genome. The number of TRs varies among EBV
episomes, resulting in different numbers and sizes of terminal repeat
fragments (Fig. 2). Analysis of the terminal fragments by Southern blot can be
used to distinguish circular and linear genomes and to establish the clonality of
tumors carrying the EBV genome. The BamNJ probe hybridizes to sequences
on both terminal fragments, and therefore detects linearized and circular forms
of the genome. The fused termini of circularized genomes yield high
molecular weight bands (8-21 kb) on Southern blot analysis; the number of
these bands correlates to the clonality of the tumor with respect to the number
of terminal repeats in the viral genome. The linearized termini of relicating
genomes result in a ladder of smaller bands (4-6 kb) which differ in size by 0.5
kb increments.
Analysis of tumor DNA using the BamNJ probe revealed the presence of
linear (replicating) forms in 5 of 9 tumors originating from 9 different PBtvlC
donors (FigA A and B). Two of 5 tumors from mice reconstituted with PBMC
from donors with latent infection, and 3 of 4 tumors from mice reconstituted
with PBMC from donors with acute 1M exhibited linear (or replicating) forms
of virus. The presence of replicating virus does not appear to be correlated with
either latent of acute infection in the PBMC donor. As expected, all of the
tumors analyzed also contained circularized EBV genome.
Most of the tumors studied (8/9) had evidence of multiple EBV episomes
(ie: contained more than one fused terminal band). Of these eight, two had a
1:1
single dominant band (tumors 6 and 9) with multiple fainter bands, while the
others had two or more (tumors 1-5 and 8) . One tumor from a mouse
reconstituted with an acute 1M donor, appeared to have a single species of EBV
present (tumor 7). These results are consistent with the interpretation that the
majority of tumors arising in hu-PBMC-SCID mice are oligo clonal, with
occasional monoclonal lesions. It has yet to be proven, however, whether
determinations of tumor clonality based on EBV TR analysis are perfectly
correlated with those based on pathologic criteria such as morphology and Ig
gene rearrangements.
iii. Clonality and histopathology. To confirm their clonality, the tumors
shown in Figure 4 were also analyzed by Southern blot using a probe which.
detects rearrangements of the Ig JH locus. Tumors which were oligoclonal for
the EBV-TR also had multiple bands on theJH blot, and these were less distinct
than the others (tumors 1 , 4, 5 6,. 8 and 9). Tumor 7, which was monoclonal for
the EBV- , had two distinct rearranged bands plus one germline-sizedband 
on the JH blot, which is consistent with monoclonality.. The other two tumors
. which had distinct rearranged bands on the JH blot (tumors 2 and 5) had single
dominant bands with the BamNJ probe; these results are consistent with each
other and with an interpretation of a single dominant clone of B cells in the
tumor, with perhaps several minor populations of EBV-infected cells present
as well.
The germline-sized bands which are seen in two of the tumors (tumors 3
and 5) are probably due to human T cells infiltrating the tumors. Most
circulating B lymphocytes have rearranged JH genes on both chromosomes
(14) (1). This would explain the faintness of the bands for tumor 3 on the
BamNJ blot, since T cells are not likely to be infected with RBV.
Histologically, the tumors tyically had the appearance of immunoblastic
large cell lymphomas, with some plasmacytic areas and small lymphocytes (Fig.
A and B). The morphology of the hu-PBMC-SCID tumor$ was very.similar
to what is reported for LPD in immunosuppressed patients. Surprisingly, only
one tumor was found to have a unique Burkitt's lymphoma-like morphology
(Fig. 6C). Tumors from mice reconstituted with PBMC from donors with acute
1M or from latently infected donors were morphologically indistinguishable
from each other.
Table 2. Incidence of LPD in hu-PBMC-SCID mice reconstituted with PBMC
from EBV-infected donors (C.B.17-SCID strain).
Type of PBMC mice with % with LPD mean days to
EBV infection: LPD / total p value LPD (S.
acute 1M 77 /118 . 65.3 83 (2)
294
latent 139/196 70. 83 (3)
total 216/314 69%
X2 P value compares percentages of mice developing LPD after reconstitution
with PBMC from donors with acute 1M or latent EBV infection.
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Table 3. Donor-related variation in the incidence of LPD in hu-PBMC-SCID
mice (C.B.17-SCID strain).
Donor Experiment Mice developing %LPD
LPD / total
3/4
4/8
5/6
0/3
3/4
3/4
6/7
3/4
3/5
0/7
0/6 '
2/2 100
6/6 100
4/5
7/9
1/4
5/5 100
10/11
3/5
9/13
0/9
21/22
6/10
12/12 100
17/18
6/8
Table 4. Surface phenotype of B-LCL, BL, and hu-PBMC-SCID tumor cells.
A. Surface phenotype of EBV-transformed B-lymphoblastoid cell lines (B-
LCL) and Burkitt's lymphoma cells (BL).
Antigen B-LCL
CDIO (CALLA)
CD19 / CD20
+++
CD23
CD30
HLA class I and II
+++
B. Surface phenotype of tumor masses from hu-PBMC-SCID mice (C.B.-17-
SCID strain).
Surface antigen
(# tumors tested)
CD45 (10)
CDIO (8)
CD19 (7)
CD20 (5)
CD23 (8)
B lymphocyte
distribution
all B lymphocytes
immature B cells
mature B cells,
B- LCL, BL
ma ture B cells,
B- LCL, BL
activated B cells
LCL
activated B cells
LCL
B cells, B-LCL 85.8 (4.
% cells expressing Ag
(SE) 1
93.4 (1.7)
9 (1.3)
66. 1 (10.
33.8 (18.
23.9 (3.5)
CD30 (3)
HLA-DR (8)
37.9 (7.
1 Suspensions of tumor cells were incubated with fluoroscein- or
phycoerythrin-labeled monoclonal antibodies and analyzed by flow cytometry.
Percentages of cells expressing Ag are those cells which displayed higher levels
of fluorescence when stained with Ag-specific Ab than with control Ab.
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Human Ig levels in hu-PBMC-SCID mice (C.B.17-SCID strain)
"' 
'0 20
mice with LPD
II mice without LPD
1 1- 5 5- 10 10- 100 100
(neg. (1+) (2+) (3+) (4+)
human immunoglobulin (ug/ml)
Figure 1. Human Ig levels were measured in
serum of C. 17-scid mice two to four weeks
after PBMC reconstitution , using a
semi-quantitative assay described in Materials
and Methods.
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Figure 2. EBV genome map and BamNJ probe hybridization patterns A.
Map of the EBV genome and location of BamNJ and Bam W probes. 
Hybridization of linear and circularEBV episomes with the BamNJ probe
demonstrates the clonality of the infection and the presence of replicating
forms of virus.
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Figure 3. LPD in hu-PBMC-SCID mice carries the EBV genome. DNA fromhu-PBMC-SCID tumor masses was digested with BamHI and hybridized with.
EBV-BamW. The BamW internal repeat band is visible, in the EBV-infected
Raji and B95.8 cell lines. All tumor masses were from the C.B. 17-SCID strain. '
Murine Raji 895.
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Figure 4. LPD in C.B.17-hu-PBMC-SCID mice contains linear and circular forms
of the EBV genome. (A) and (B) are two exposures of a Southern blot of DNA
from C.B.17-SCID human LPD. DNA was digested with BamHI and hybridized
with BamNJ Bands larger than 8 kb are the fused termini of circular
, non-
replicating EBV; 4-6 kb bands are the termini of linear, replicating EBV. The
B95.8 cell line contains latent and replicating episomes. Tumors 1 through 9
represent the same tumors shown in Fig. 3, but are rearranged according to the
type of PBMC donor (latent= tumors from mice reconstituted with PBMC from
latently-infected donors; acute= tumors from mice reconstituted with PBMC
from donors with acute 1M).
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Figure 5. Immunoglobulin JH gene rearrangements in LPD from hu-PBMC-
SCID mice. DNA from hu-PBMC-SCID LPD was digested with HindIII and
, hybridized with the JH probe. Germline JH'is visable as an llkb fragment in
the lane labelled"T cell" (DNA from the T cell line C8166). Raji is a
monoclonal Burkitt's lymphoma cell line. (Tumors 1 through 9 are in the same
order as in Fig. 4.
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Figure 6. Morphology of representative tumors arising in hu-PBMC-SCID
mice (C.B. 17--SCID strain). A. A typical tumor consisting predominantly of
immunoblasts (arrow); B. A minority of tumors contained areas of
plasmacytic cells (arrow); C. A single mouse produced several tumors with
morphology typical of BL. Magnification=400x with water immersion; bar = 5
microns. --
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2. Adoptive transfer of cytotoxic T lymphocyte lines into hu-PBMC-SCID
mice.
The preceding results indicate that reconstitution of the SCID mouse with
. PBMC from EBV-seropositive donors could be used as a small animal model '
EBV-associated LPD. The experiments which follow were conceived and
designed to answer the question: can EBV-specific CTL prevent the outgrowth
(from PBMC) of EBV -positive LPD in vivo? The approach taken was to
provide reconstituted SCID mice with adoptive immunotherapy in the form of
EBV-specific CTL lines or alloreactive CTL lines.
a. Phenotype, activity and specificity of CTL lines. T cell lines with
cytotoxic activity directed against the EBV latent proteins are easily established
from the PBMC of an EBV seropositive individual by multiple rounds of
stimulation in vitro with autologous B-LCL. Cytotoxic T cell lines which
recognize HLA class I alloantigens can similarly be established by stimulation of
PBMC with class I-mismatched B-LCL. CTL lines generated in this manher are
nearly always HLA class I-restricted and CDS positive. Flow cytometric analysis
of the CTL lines used in the adoptive transfer experiments which follow
demonstrate that, typically, 87% or more of the cells were CD3+ and 80% or,
more were CD8+ (Fig. 7). Occasionally cell lines were generated in which 50%
or more of the cells were CD4+; these cells invariably exhibited very low levels
of lysis in cytotoxicity assays and were not used for adoptive transfer.
The specificity of CTL lines for EBV antigens and their HLA restriction is
demonstrated by their abilty to recognize and lyse autologous Cr-labelled B-
LCL in cytotoxicity assays (Fig. 8). Autologous B-LCL and hu-PBMC-SCID
tumor cells generated from the same individual's PBMC were lysed equally
well by EBV-specific CTL. Substantially lower levels of lysis of HLA-
mismatched B-LCL by these CTL indicated that most of the lytic activity is HLA
restricted. Alloreactive CTL lines recognized and lysed allogeneic B-LCLs
(which were also the stimulator cells) to a much greater extent than autologous
LCLs (Fig. 10).
The lytic activity of the CTL lines against their specific target cells was
standardized by determining the lytic units (L.U. ) of activity for each cell line
just prior to their injection into hu-PBMC-SCID mice (Figs. 9 and 10).
b. Delay of LPD with CTL immunotherapy. SCID mice were reconstituted
with PBMC from EBV -seropositive donors, and treated with CTL lines
established from the same donor s PBMC. Immunotherapy consisted of 100-
200 L.U. of EBV-specific CTL injected i.p. twice per week
, with the initial
injection occurring on day 0 to day 3 after PBMC reconstitution (Table 5). To
control for virus specificity and HLA restriction or CTL-induced effects, a group
of mice was injected with ailoreactive CTL on the same schedule. The
alloreactive CTL were generated from the same PBMC donor and exhibited
very low levels of lysis against autologous B-LCL (Fig. 10). Van Kuyk et al have
shown persistence of CTL clones for only 3 to 4 days after injection into hu-
PBMC-SCID mice (92); therefore, in these experiments, mice were given CTL
twice weekly.
The cumulative survival of hu-PBMC-SCID mice receiving EBV-specific
CTL in two experiments was significantly increased compared to untreated
mice (p=0.006; Table 5 and Fig.11). Survival increased even more significantly
when mice were treated withalloreactive CTL (p=0.00Q8;). Either type of CTL
immunotherapy resulted in a delay in tumor outgrowth, but did not
completely prevent tumors from developing. Surviving mice were sacrificed
on day 90 (untreated and aUo-CTL treated) or day 95 (EBV-CTL treated) and
examined for LPD. One of 23 untreated mice (4.3%), 3/13 mice treated with
EBV-specific CTL (23.1%), and 2/9 mice treated with alloreactive CTL (22.2%)
were free of tumors at the end of the experiment. The differences in tumor
frequency were not statistically significant by X analysis or Fischer s exact test.
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Table 5. Survival of hu-PBMC-SCID mice (C.B.17-SCID strain) after adoptive
transfer of CTL.
CTL expt CTL therapy duration of mean P-value for
specificity (n). inititated 1 therapy survival survival vs.
. (weeks)2 (S. ) (days) untreated3
EBV 1 (6) day 0 10. 77.2 (3.48) 006
2 (7) day 3- 6.4
Allo (9) day 0 , 78.0 (2.27) 0008
untreated (23) 64.3 (2.10)
1 day after reconstitution
2 treated mice received 100-200 LU of CTL twice weekly.
3 by logrank (fvlantel-Cox) test; EBV-CTL value was calculated for expt.l +
expt. 2 vs. untreated controls.
Fig. 7. Flow cytometric analysis of CTL lines. Percentages of cells expressing
CD3, CD4 or CD8 are indicated in each quadrant.
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Figure 8. Lysis of autologous B-LCL, HLA-class I-mismatched B-LCL and hu-
PBMC-SCID mouse tumor cells by EBV-specific CTL lines.
Lysis of hu-PBL-SCID tumor cells by EBV-specific CTL lines
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Figure 9. Determination of lytic units (L.U.) of EBV-specific activity /106 CTL.
EBV-specific CTL lines averaged 36 L.U. /106 CTL. Mice were injected 2x/week
with between 3x106 and 6x106 CTL (100-200 L.U.
Lytic activity of EBV-specific CTL
100
-- 
Autologous B-LCL
''',,,,,0,,,,,,, HLA class I mis-matched B-LCL
.................... .........................
0"'''''''''''''''''''''''''''''''''''''''''
cell # x10 000
Figure 10. Determination of lytic units (L.U.) of alloreactivity /106 CTL.
Alloreactive CTL averaged 20 L.U./106 CTL. Mice were injected 2x/week with
approximately 100 L.U.
Lytic Activity of Alloreactive CTL
100
Autologous B-LCL
"",,,.0,,.,,, HLA Class I mis-matched (stimulator) B-LCL
cell# x10 000
Figure 11. Increased survival of hu-PBMC-SCID mice treated with CTL.
Mortality was due to LPD in all cases. Reconstituted mice injected twice weekly
with EBV-specific CTL lines or alloreactive CTL lines survived significantly
longer than did PBS-injected mice (p=0.006 and 0.0008 respectively).
100
Untreated (n=23)
EBV-CTL treated (n=13)
Allo-CTL treated (n=9)
100
days post-engraftment
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B. Experiments in NOD-SCID mice.
1. Immune reconstitution of NOD-SCID mice with PBMC from
individuals with acute or latent EBV infection.
a. High levels of human T lymphocyte engraftment. Initial
experiments characterizing immune reconstitution of the NOD-SCID strain of
mice were performed by Dr. R. M. Hesselton; a breeding colony of NOD-SCID
mice was subsequently established at the U. Mass. Medical Center Animal
Medicine facilty. In these-experiments, human PBMC engraftment in spleens
of NOD-SCID mice was significantly increased (5-10 fold) after injection of
human PBMC, compared to reconstitutedCB.17-SCID mice (Fig. 12) (22). The
human cells in the spleen were almost entirely CD4 and CD8 single-positive T
cells, and expressed the CD45RO (activated/memory cell) phenotye (22).
Further reconstitutions of NOD-SCID mice with human PBMC were
performed to determine whether EBV-associated LPD would also develop in
this strain of SCID mouse, and with what frequency. Human cells in the
spleens of reconstituted NOD.,SCID mice were again found be almost
exclusively CD3+ (Table 6).
b. Comparison of the frequency of lymphoproliferative disease.
NOD-SCID mice were reconstituted according to the same protocol used for
CB.17-SCID mice, using PBMC from six donors with acute 1M and three donors
with latent EBV infection. The overall frequency of LPD was significantly
lower in reconstituted NOD-SCID mice than in C.B.17-SCID mice (58% vs. 69%
p=0.029) (Tables 2 and 7). In contrast to the findings in reconstituted C.B.17-
SCID mice, the frequency of LPD was significantly higher in NOD-SCID mice
engrafted with cells from donors with acute 1M than in NOD-SCID mice
engrafted with cells from latently-infected donors (Table 7). The two latently-
infected PBMC donors used to reconstitute NOD-SCID mice were known to
generate a high frequency of LPD in CB.17-SCID mice. When the results of
reconstitution of CB.17-SCID and NOD-SCID mice with just these two donors
are compared, the difference in the frequency of LPD is striking: 89% of CB.17-
SCID mice developed LPD compared to 50% of NOD-SCID mice (Table 8).
c. Characterization of LPD in reconstituted NOD-SCID mice.
i. Cell surface phenotype. Tumor masses from reconstituted
NOD-SCID mice were analyzed by flow cytometry to determine if their surface
(Cccc:r-
antigen phenotype differed in any way from masses found in CB.17-SCID mice.
Tumors arising in the two strains of mice did not differ markedly in expression
of any of the surface antigens tested (Table 4 and 9). A substantial percentage of
human T cell were identified in masses from NOD-SCID mice; however
comparisons cannot be made with CB.17-SCID masses as these were not
stained with the CD3 antibody.
ii. Presence of EBV genome and replicating viral forms. Evidence
of EBV replication was found in 12/23 tumors from NOD-SCID mice (Fig. 13);
this frequency is similar to that seen in CB.17-SCID mice (5/9 tumors, Fig. 4).
Several of the tumors in Figure 13 appear not to carry the EBV genome; these
tumors were determined by surface marker analysis to be murine thymic
lymphomas, which frequently occur in older NOD-SCID mice and are
associated with the expression of ecotropic murine leukemia provirus Emv30
(60). The murine tumors were also found to metastasize from the thymus to
other sites, usually lymph nodes in the abdomen. Surface marker staining of
NOD-SCID tumor masses occasionally revealed a predominance of CD3+
human T cells.
Not surprisingly, the tumor masses arising in NOD-SCID mice appear to
be identical to those arising in CB.17-SCID mice with regard to cell surface
phenotype, presence and clonality of the EBV genome, and frequency with
which replicating episomes are found. LPD from the two SCID strains were
also found to be very similar histologically (data not shown).
d. Wasting disease in PBMC-reconstituted NOD-SCID mice. A
phenomenon which was not seen in CB.17-SCID mice was observed in some
reconstituted NOD-SCID mice in necropsies performed at least eight weeks
after reconstitution. Affected mice were small in size and appeared anemic and
cachectic, with pale internal organs and no body fat. Spleens were usually very
small, pale to white, and fibrous. In general, very few viable cells could be
recovered from these spleens. These mice often had a scaley dermatitis and
hair loss. Mice affected by this syndrome were free of human LPD
, and always
produced greater than 1 mg/ml of human Ig. The syndrome has not been
observed in unreconstituted NOD-SCID mice.
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Table 6. Surface phenotype of spleen cells from hu-PBMC-SCID mice (NOD-
SCID strain).
Surface antigen
(# spleens tested) lymphocyte distribution
% cells expressing Ag
(SE)l
untreated mice:
CD45 (6)
CD3 (7)
all lymphoid cells 48.2 (11.
45.9 (11.0)immature B cells, BL
CD4 (4)
CD8 (4)
helper T cells
cytotoxic T cells
36;0 (12.
26.0 (4.
ant1-CD8-treated mice:
CD45 (7) 
CD3 (10)
19. 1 (4.
11.5 (2.
16.2 (3.4)
.:0 1 (0)
1.9 (0.
CD4 (4)
CD8 (7)
Goat anti-mouse Ig (6) control for Ab-coated
cells
ISuspensions of tumor cells were incubated with fluoroscein- or
phycoerythrin-labeled monoclonal antibodies and analyzed by flow
cytometry. Percentages of cells expressing Ag are those cells which
displayed higher levels of fluorescence when stained with Ag-specific Ab
than with control Ab.
Table 7. Incidence of LPD in NOD-SCIDmice injected with PBMC from
EBV -infected donors.
PBMC EBV mice with with LPD mean days to
infection type: LPD / total
p value LPD (S.
acute 1M 47/73 67. 88.2 (4.
latent 29/58 50. 049 69.3 (3.5)
total 76/131 58.
P value compares percentages of mice developing LPD after
reconstitution with PBMC from donors with acute 1M or latent EBVinfection.
Table 8. Comparison of incidence of LPD in CB. 17-SCID and NOD-SCID
mice.
PBMC donor SCID strain Mice with % with LPD
LPD / total
p value
CB.- 35/38
CB.- 27/32
total CB.-17-SCID 62/70
NOD 4/12
. PM NOD 25/46
total NOD-SCID 29/58 0(0.0001
1 Reconstituted with PBMC from donors with latent EBV infection.
2 X P value compares incidence of LPD in C.B.-17-SCID and NOo'-SCID mice. '
, "f
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Table 9. Surface phenotype of tumor masses from hu-PBMC-SCID
mice (NOD-SCID strain).
Surface antigen B lymphocyte % celis expressing
(# tumors tested) distribution Ag (SE)l
CD45 (16) all B lymphocytes 70 (3)
CD3 (26) T cells 20 (3)
CD4 (16) helper inducer T cells 14 (3)
CD8 (4) cytotoxic T cells 19 (3)
CD20 (23) B cells, B- 21 (3)
lymphoblastoid cells
CD23 (4) activated B cells, B- 24 (12)
lymphoblCistoid cells
CDlO (2) immature B cells, BL , 0. 10 (0.
(CALLA)
ISuspensions of tumor cells were incubated with fluoroscein- or
phycoerythrin-labeled monoclonal antibodies and analyzed by flow cytometry.
Percehtages of cells expressing Ag are those cells which displayed higher levels
of fluorescence when stained with Ag-specific Ab than with control Ab.
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12. Recovery of human cells from spleens of hu-PBMC-SCID mice.
o C. 17-SCID
11 NOD/LtSz-SCID
WEEKS AFTER ENGRAFTENT
Figure 12. Percentage of human cells present in spleens of
17-SCID and NOD-SCID mice after Lp. injection of with 20 x 106human PBMC. Between 6 and 10 animals were tested at each timepoint. Statistically significant comparisons are inqicated by *
: p..
. 0.05 for NOD-SCID vs, C. 17-SCID. From Hesselton
, et aI. , 1995 , J.Infect. Dis. (61). 
Figure 13. LPD in hu-PBMC-SC1D mice (NOD-SCID strain) contains linear
and circular forms of the EBV genome. Tumor DNA was digested with BamH1
and hybridized with the BamNJ probe. Lat. : tumors from mice reconstituted
with PBMC from la.tently-infected donors. 1M: tumors from mice reconstituted
with PBMC from donors with acute 
EBV-BamNJ Southern blot:
Hu-PBMC-SCID Tumor DNA
I.M. Lat. I.M. Lat. I.M Lat.II II II 
1 2 3 4 5 6 7 8 9 10 11 12131415 16 171819 20 21 22 23
9.4kb-
23. 1 kb-
5kb-
f .
2. CD8+ T cells protect NOD-SCID mice from LPD.
a. Depletion of engrafted CD8+ cells increases the frequency of LPD to
100%. EBV-associated LPD is believed to be prevented in healthy human hosts
by EBV -specific CTL. In this context, the coincidence of high levels of T cell
engraftment and relatively low LPD in reconstituted NOD-SCID mice suggests a
causal relationship between the two observations. To investigate this
possibilty, monoclonal antibodies were employed to deplete CD4+ and CD8+
human T cell subsets from reconstituted mice. Ab-mediated depletion was
successful when purified OKT4 (anti-CD4) and OKT8 (anti-CD8) antibodies
were ' injected i.p. ill.to mice with established PBMC grafts (Fig. 14.). One week,
after the Ab injections, spleens of mice receiving a single injection of OKT40r
OKT8 contained less than 0.5% of cells bearing the respective surface marker.
Treatment with OKT4 at early timepoints after reconstitution (0-3 days)
had another significant effect: one injection of OKT4 completely prevented the
engraftment of all human T cells in the spleen (Fig. 15, G-I). Injection of OKT8
at early timepoints, as at the later timepoint, prevented only CD8 T cells from
engrafting in the spleen (Fig. IS, D-F). The possibilty that the presence of CD4,
or CD8 cells was simply being masked by Ab coating was ruled out in two ways:
first, the percentage of CD3+ T cells was in all cases very similar to the.
percentage of either CD4+ or CD8+ when the reciprocol population had been
depleted; i.e. all of the CD3+ cells were also CD4+ when CD8 T cells were
depleted, and vice versa. Second, cells were stained with with fluorescein-
labelled goat-anti-mouse Ig, which would bind to cells coated with mouse mAb.
No significant staining was ever seen with the goat anti-mouse reagents in Ab-
treated animals (Table 6). These results indicate that CD4+ T cells or their
secreted products are required for efficient human lymphocyte engraftment. 
is important to note that all of the OKT4-treated mice produced HuIg, although
at lower levels than untreated mice without LPD, indicating that B cells are
indeed engrafting in these mice.
When Ab-treated mice were observed for a period of up to 16 weeks, the
incidence of LPD was significantly increased in anti-CD8-treated mice compared
to control mice (100% vs. 47%, p-cO.OOOl;Table 10, groups A and B). The
incidence of LPD decreased significantly in anti-CD4-treated mice (11% vs. 47%,
'1::
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p=0.007; groups A and C). Although very few to no CD16+ cells are detectable
in hu-PBMC-SCID mice of either strain, the possible influence of NK cells on
LPD was investigated by injecting mice with a mAb which recognizes the NK
cell marker CD16 (B73.1). As expected, anti-CD16 treatment did not have a 
significant effect on the incidence of LPD (47% vs. 35%; Table 10, groups A and
D), The effects of OKT4 and OKT8 treatment on cumulative survival were ,
expected: OKT4 significantly increased survival time and OKT8 significantly
decreased survival time, while B73.1 had no effect (Table 11). These results'
suggest that CD8+ T cells provide protection from LPD in about half of ,
reconstituted NOD-SCID mice, and that CD4+ T cells or their secretedproduds
are required for the generation of LPD.
, '
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Table 10. CD8+ T cells protect PBMC-reconstituted NOD-SCIDmice from EBV-
associated lymphoproliferative disease.
Treatment group 
(PBMC-reconstituted
mice)
A. cQntrol4
(4 experiments)
Mice with
tumor / total
16/34
% mice
with
tumor
P-value vs
control2
value vs
anti-CD83
B. anti-CDS mAb
(3 experiments) 20/20 100 ..0.0001
C. anti-CD4 mAb
(2 experiments) 2/19 007
D. anti-CD16 mAb
(2 experiments) 6/17
E. anti-CD8 + CD8+ T
cells (1 experiment)
1/10 034
.:0.0001
F. anti-CD8 + CD4+ T
cells (1 experiment)
7/9
1 NOD-SCID mice in were injected ip with PBS or mAbs once, on day 0-3 afterPBMC-reconstitution; mice in groups C and D were also injected i.p. 
with
purified CD4 + or CD8+ T cells on days 15 and 34.
2 X value for LPD incidence vs. control.
3 X P-value for LPD incidence vs. anti-CD8-treated mice (group B).4 Control mice were injected with PBS in 3 experiments and control MAb in
one experiment.
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Table 11. Effect of CD4 and CD8 T cell depletion and reconstitutiOrlon survival
of PBMC-reconstituted NOD-SCID mice.
Treatment group (n)l mean days
survived (SE)
73.9 (4.
P-value vs
control2
P-value vs anti-
CD83
A. control (34)4
(4 experiments)
B. anti-CD8 mAb (20)
(3 experiments)
48.7 (0. ..0.0001
E. anti-CD 4 mAb (19)
(2 experiments)
111 (5. ..0.0001
F. anti-CD16 mAb (17)
(2 experiments)
79 (4.
C. anti-CD8 + CD8+ T cells
(10) (1 experiment)
63.5 (6.4) 003
D. anti-CD8 + CD4+ T cells 41.3 (1.7)
(9) (1 experiment)
0002 002
1 NOD-SCID mice were injected ipwith PBS or mAbs once, on day 0:-3 after
PBMC-reconstitution; mice in groups C and D were also injected ip with
purified CD4 + or CD8+ T cells on days 15 and 34.
2 T -test p-values for cumulative survival of treated groups vs. control group.
NS=not significant.
3 T- test p-values for cumulative survival of treated groups vs mice receiving
anti-CD8 only (group B).
4 Control mice were injected with PBS in 3 experiments and control IvlAb in
one experiment.
r=u
Figure 14. Antibody-mediated depletion of human T cell subsets in mice with
established PBMC grafts. NOD-SCID mice were injected i.p. with OKT4 (anti-
CD4), OKT8 (anti-CD8), or PBS six weeks after PBMC reconstitution. Spleencells were analyzed for the presence of human lymphocytes one week later.
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Figure 15. Anti-CD8 treatment at the time of PBMC reconstitution prevents
engraftment of CD8 T cells in the spleen; and anti-CD4 mAb prevents
engraftment of all human cells. NOD-SCID mice were injected i.p. with MAbs3 days after PBMC reconstitution; spleens were analyzed for the presence ofhuman cells 4.5 weeks later. 
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Figure 16. A'doptively transferred CD4+ or CDB+ T cells traffic to the spleen of
CDB-depleted inice. NOD-SCID mice .were injected i.p. 
with OKTB mAbimmediately after reconstitution and with purified 
CD4+ or CDB+ cellpopulations (5-10 x 106 per injection) on days 16 and 34 after reconstitution.
Spleens were analyzed for the presence of human cells at sacrifice (6 weeks for
mouse receiving CD4+ cells and 
10 weeks for mouse receiving 
CDB+ cells).
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b. Adoptive tran fer of CD8+, but not CD4+, T cells restores protection
from LPD The increase in LPD and decrease in survival which accompanied
depletion of CD8+ cells may be attributable to the absence of cells which have
the effector functions of CD8+ T cells (ie: antigen-specific cytolytic activity) or
which secrete pecific cytokines; it may also simply be the result of a 
reduction
in the total riumber of engrafted T cells. In the latter case, replenishment with
T cells of either phenotype should restore the protection from LPD. which is
seen in about halfof control mice; if the former is the case, replenishmef)t of
CD8+ cells would be required to provide such protection. The requirement for
CD8+ T cells for protection was established by adoptive' transfer of T cell subsets
into CD8-depleted mice. The 50xl06 PBMC injected to reconstitute each mouse
would be expected to contain approximately 22x106 (44%) CD4+ T cells and
16.5xl06 (33%) CD8+ T cells. To replace the depleted CD8+ cells with an
approximately equal number of purified CD4+ or CD8+ cells, mice Were
injected with lOx106 and 5xl06 CD4+ cells:on days 16 and 34 after 
. reconstitution, or with 7.5xl06 and 8.5x106 CD8+ cells on days 16 and 34 after
reconstitution.
Adoptive transfer of CD8+ T cells provided a highly significant level of
protection from LPD: only one of 10 mice developed LPD after receiving anti.,
CD8 followed by CD8+ T cells, compared to 20/20 receiving anti-CD8 alone
(p=O.OOOl, Table 10). In contrast, 70f 9 mice receiving CD4 + T cells after CD8
depletion developed LPD (p=0.03 vs. anti-CD8 alone, Table 10). The two mice
in this group which did not develop LPD became moribund and were sacrificed
in the fourth week of the experiment. Both animals had gross indications of
graft V8. host disease (GVHD), which was probably caused by the injection of
additional CD4 + T cells. The level of protection provided by CD8+ T cells was
signifcantly higher than that provided by CD4+ T cells (X p=0.003).
F ACS analysis at the time of sacrifice revealed a large population 
of CD4 +
cells in spleens from mice receiving CD4+ T cells (Pig. 16A-C). Likewise
adoptive transfer of CD8+ T cells resulted in a large CD8+ population
, as well as
a smaller CD4+ population, in the spleen when analyzed at the time of sacrifice
(Pig 16B), confirming that the purified T cell subpopulations also traffic to and
populate the spleen.
The effects of antibody treatments on the incidence of LPD were expected
to also be reflected in survival times. As expected, cumulative survival time of
anti-CD8-treated mice was significantly shorter than both control and anti CD8
plus CD8 T cell-treated groups, and survival of anti-CD4-treated mice was
significantly longer (Table 11).. ..The shortest mean survival times were seen in
the group that received CD4+ T cells after CD8 depletion; this was due to the
short survival of two mice which developed GVHD. Surprisingly, though
survival time was not signifcantly longer for mice receiving CD8+ T cells after
CD8-depletion than for controls. The reason 'for this appears to be that
although most of the mice in this group did not- develop lethal LPD.. they ,did
develop a wasting syndrome (described earlier) at about the same time control
mice were developing tumors. 
Mice treated with anti-CD4 Ab had the longest survival times. While,
several of these mice eventually developed LPD, none of the others had signs
of the wasting disease, which appears to be a T cell mediated phenomenon.
These results of these experiments do not distinguish -whether CD4 + or CD8+ T
cells are responsible, since depletion of CD4 + cells prevents engraftment of
CD8-f cell, and depletion of CD8+ cells usually leads to death due to LPD before
the onset of the wasting syndrome.
CHAPTER IV. DISCUSSION
A. Experiments in C.B.17-SCID mice.
1. Comparison of immune reconstitution with PBMC from two types ()f
EBV-infected donors.
. a. Frequency and characterization of LPD. Reconstitution of C.B.17-
SCID mice with PBMC from EBV -infected donors in most cases led to the
deveiopmentof LPD that shared many of the characteristics of
immunosuppression-associatedimmunoblastic , B cell lymphoma in humans.
The frequency of LPD and survival time of affected mice were similar when.
mice were reconstituted with PBMC from donors with acute IM or with latent
EBV infection. In all cases LPD carried the EBV genome (Fig. 3), expressed
surface antigens similar to those found on B-
LCL (Table 4)1 were
predominantly oligoclonal with respect to immunoglobulin gene
rearrangements (Fig. 5) and EBVgenome (Fig. 
4)1 and typically displayed
immunoblastic morphology (Fig; 6). Each of these characteristics of LPD
, '
arising in hu..PBMC-SCID mice is similar to immunosuppression-induced
LPD and distinguished the SCID mouse tUmors from Burkitt' s lymphoma.
. Similar findings have aJsobeen reported by several other groups(10ro). 
The observation that reconstitution with PBMC from donors with either
acute or latent EBV infection results in similar high frequencies of LPD
suggests that the transplanted CD8 T cells do not suppress EBV-induced B cell
proliferation to a great extent in this mbdet as they are thought to do in the
human host. If it is assumed that CD8+ T cells have an effect on LPD one
would predict that reconstitution with PBMC from donors with acute and
latent infection would have different outcomes due to the differences in
composition of their T cells at:d the proportion of EBV -infected B cells. In
acute IM a high percentage of Tcells in peripheral blood are activated (86)1
making them highly susceptible to activation-induced apoptosis (33). In
addition the percentage of B cells that are infected with 
EBV is 10- to 000-
fold higher during acute 1M than in latent infection (45 99). If the T cells
from acute 1M patients undergo apoptosis at a high rate compared to those
from lateFitly infected donors after transplantation into SCID mice
, then a
higher rate of LPD (up to 100%) would be predicted in mice receiving acute 
PBMC due to the large number of EBV-infected B cells present. However
, if
the cytotoxicity directed against EBV-infected cells present in acute 1M PBMC is
preserved after transplantation, then in mice receiving these cells; the rate of
LPD would be predicted to be lower than 100%.
, The rate of LPD after
reconstitution with acute 1M PBMC was lower that 100%, but not dramatically,
so. This could be a result of the effects of acute 1M activated T cells, or simply
due to decreased survival of B cell tumor precursors, which are also activated.
by EBV infection. The results of these experiments do not distinguish between
these two possible effects on the development LPD.
Several lines of evidence support the conclusion that the injected human
T cells do not significantly affect the development of LPD in reconstituted
SCID mice. First, the most common sites for LPD in hu-PBMC-SCID mice are
the liver and hepato-pancreatic and mesenteric lymph nodes (our
unpublished observations). In contrast, the majority of transplanted T cells
colonize the peritoneal cavity, forming foci on the serosal peritoneum (31). ' A
study which used fluorescence in situ hybridization techniques to detect
human cells in hu-PB1vlC-SCID mice revealed that most of the human T cells
remained in the peritoneal cavity, with very low percentages of T cells being
detected in lymphoid organs (40). Others, however, have reported finding that
from 0% to 57% of hu-PBMC-SCID spleen-cells stained positively for human T 
cell antigens (34 84). Second, T cells recovered from reconstituted SCID mice
. have been reported to be anergic to activation via the T cell receptor (84). The
presence of T cells in the PBMC inoculum has been shown to be required for
Hulg production and the generation of LPD in hu-PBMC-SCID mice (93).
These findings suggest that human T cells transplanted into SCID mice
provide help for Ig production and B cell proliferation in the form of cytokine
secretion, but they may not be capable of providing other effector functions or
of normal trafficking outside of the peritoneal cavity, both of which are
neccessary for suppression of Bcell proliferation. The results of reconstitution
using PBMC from donors with acute 1M and latent EBV infection described
above are consistent with this interpretation
, which in turn implies decreased
survival of B cells from acute 1M PBMC donors.
b. Comparison of rates of reconstitution. The rate of successful
reconstitution of CB.17-SCIDmice was.higher whenPBMC from donors with
latent EBV infection were used than when PBMC were from donors with
acute 1M. That is, a higher percentage of mice injected with PBMC from.
latently-infected donors produced significant levels of human Ig (90% with
latent vs. 75% with acute). A possible reason for this difference again lies in
the T cell composition of the injected PBMC As previously mentioned , T
cells are neccessary for human Ig production and tumor induction in hu-
PBMC-SCIDmice; mice injected with purified. B cells do not make human Ig
nor do they develop LPD (93). If the acute 1M T cells have a shorter half-life in
SCID mice as a result of increased apoptosis
, then it is possible that in some
mice the number of surviving T cells is insufficient to support Ig production.
The frequency of such mice would be higher among those injected with acute
I!\1 PBMC than those injected with latently-infected PBMC 
. .
Another possible reason for the difference in reconstitution success
relates to the fact that successful reconstitution is dependeht upon the number
of B cells injected (46): vVhile the percentage of B. cells . in PBMC from acute. 
donors was one.,forth to one-half that oflatently-infected donors (1-4% vs. 4.:
. 8%), a relatively large proportion of these cells are EBV-infected and hence.
activated. The rate of LPD in mice reconstituted with acute 1M donors
indirectly implies that these activated B cells may have a shorter survival time
after injection. Either of these factors (increased apoptosis of T cells or Bcells
due to activation) could be responsible for the lower rate of reconstitution
with acute 1M PBMC
c. Variabilty in the abilty ofPBMC donors to generate LPD.
Substantial variabilty in the abilty to generate LPD in hu-PBMC-SCID mice
was seen among individual latently-infected PBMC donors (Table 2). This was
also the case with acute 1M donors. Similar variabilty was also reported by
Picchio et aL, along with the finding that replicating forms of EBV were always
present in tumors from mice reconstituted with so-called "high
incidence donors (57). More than half of tumors from mice reconstituted
with "intermediate-low incidence" donors also had evidence of EBV
replication. My analysis of EBV replication did not include a large enough
sample to corroborate or refute these findings. Picchio suggests that lower
levels of EBV-specific immunity in high .incidence donors might allow
activation of EBV replication and new infection of B cells. The previously-
mentioned evidence that T cell immunity is not active after reconstitution
argues against this theory. An alternative explanation is that the variabilty in
frequency of LPD reflects differences in the number of EBV-infected B cells in
the PBMC inoculum; this would also explain the variability seen between
different experiments using the same donor, since the frequency of EBV-
infected B cells is known to fluctuate over time in infected individuals (45).
2. Cytotoxic T lymphocytes delay LPD in hu.,PBMC-SCID mice.
EBV -specific cytotoxic T cells are often cited as the main factor 
protecting immunocompetent, infected individuals from EBV-associated LPD.
This proteCtion has not been demonstrated in vivo .due to the lack of an
adequate animal model of the disease. Such a model is now provided. by the
hu-PBMC':SCID mouse. 
The results of adoptive transfer of CTL lines into hu-PBMC.SCID mice
described here demonstrate that cytotoxic T cells can delay, 'and in some cases
prevent EBV-associated -LPD. This delay was seen when. the injected CTL
specifically recognized EBV latent proteins, and also whenCTL specifically
recognized HLA class I alloantigens (Fig. 11 and Table 5). The delay in LPD
observed following injection of EBV.specific CTL was presumably due to HLA. 
class I-restricted CTL lysis of EBV- infected tumor cell precursors in vivo. .
However, since lysis of autologous EBV-infected target cells by the alloreactive
CTL lines in vitro was very low (compared to lysis of allogeneic target cells),
is unlikely that delay of LPD following in vivo administration of alloreactive
cells is mediated by direct lysis of tumor cell precursors by HLA-restricted
recognition of viral antigens. While the allogeneic targets are infected with
EBV, they do not share any HLA class I alleles with. the CTL; the mechanism
for the delay of LPD following the administration of alloreactive CTL is
therefore neither virus specific norHLA-restricted. These results demonstrate
contributions by two distinct. mechanisms of tumor suppression in vivo.
Two mechanisms could be responsible for the non-specific suppression of
. LPD by alloreactive CTL. The first possibility is that the CTL secrete cytokines
which suppress tumor outgrowth. HIV- l-specificCD8+ CTL have been
shown to produce tumor necrosis factor-a, interferon-
...
granulocyte/macrophage colony-stimulating factor
, and low amounts of
interleukins 2, 3, and 4 (59). One or more of these cytokines could either
. directly suppress EBV-transformed BceUs or have an indirect effect-by
influencing intact murine inate immune functions. An example of the latter
is the prevention of tumors by low concentrations of IL-2 in hu.,PBMC-SCID
mice, due to activation of murine NK cells (4). Expression of a transfected, 
interferon-g gene in tumor cells leads to growth inhibition of the tumor
when T cells are also present (18). Growth inhibition is also seen in the
absence of T cells when tumor necrosis factor is expressed in, tumor cells. (53). .
Despite a relatively large L.U. dosage of CTL
, adoptive immunotherapy,
did not completely protect mice from LPD. Previously published studies
provide clues to why protection by CTL was not complete in hu-PBMC-SCID
mice. .HIV- specific CTL injected into hu-PBMC-SCID mice were cleared from
the peritoneal cavity by day five (92). Cells recovered from the peritoneal
, . cavity through day four retained cytotoxic activity, indicating that CTL
function was not inhibited after adoptive transfer (ie: the CTL did not appear
to be anergic). 
. There are several reasons why CTL might have such a short survival,
time after injection into SCID mice. Fir endogenous NK cell activity is
retained in the SCID mou , and may even be higher than in non-SCID mice.
Gamma-irradiation of SCID mice prior to reconstitution to inactivate
endogenous NK cell activity has been shown to increase human
immunoglobulin levels. While the authors suggest that mouse NK cells may
suppress Ig production by B cells or B cell engtaftment
, they may also reduce
longevity of inected T cells and CTL lines. Depletion of endogenous NK cells
prior to. reconstitution might therefore increase the lifespan of T cells in SCID
mice and the effectiveness of CTL immunotherapy. The results of
experiments in NOD-$CID mice, described below, support this view. Second
the absence of growth factors, especially IL- , could be causing the CTL to be
short-lived. Hu-PBMC-SCID mice could not be given IL-2 in these.
experiments, because its proliferative effect on murine NK cells has been
shown to prevent EBV-induced LPD (4).
Other groups have reported using EBV-specific CTL to treat LPD in SCID
mice which had been injected with EBV-transformed lymphoblastoid cell
lines (9, 65). Boyle et al reported results which were similar to those described
here: CD8+ CTL conveyed partial protection from tumors
, and significantly
delayed tumor outgrowth in unprotected mice. Rencher et al reported
complete protection from LPD with injection of CD8+ or mixed T cell lines
(65). In both of these -studies, however, LPD was induced by injecting B-LCL
as opposed to PBMC in the study reported here. Recently, the phenotypeof
the cells which are latently infected with EBV 
in vivo has been described (45).
The cells bear the phenotype of resting B cells
, and lack expression of the
lymphoblastoidantigens found on B-LCL. The EBV-infectedcells in the
PBMC injected into SCID mice must undergo a phenotypic change before they
develop into LPD, and are therefore distinct from B-LCL. Thisdistinction
could explain why CTL are less effective in protecting PBMC-injectedmice
from LPD than they are B-LCL-injected mice.
Evidence for protection from EBV 
-associated LPD has also been reported
in human patients treated with EBV-specific T cells (26, 68) or purified donor T
cells (54) following T-depleted bone marrow transplantation. Infused EBV-
specific CTL persisted in recipients for extended periods, EBV DNA levels
. decreased, andLPD was' resolved. , While it is more difficult to assess the effects
of CTL treatment in these human studies, there ,are several reasons it is
unli ely tha,t the outcome of these CTL infusioDS was due to a recovery of host
immunity. First, the timing of the therapeutic effects was very closely
correlated with CTL inusions; second, virus-specific.T cell immunity is
generally impaired for up to a year after BMT
, and third, spontaneous
resolution of EBV-induced LPD occurs very rarely (68 ).
Infusion of unmanipulated donor T cells was also effective in inducing
. remission of LPP, but was associated with the clinical complications of graft-
versus-host disease and lethaUnflammatory responses (54). This toxicity is
thought to be due to the presence of alloreactive T cells in the infusion, and
may be avoided by the use of EBV-specific CTL (27).
B. Experiments in NOD-SCID mice.
1. Immune reconstitution of NOD-SCID mice with PBMC from EBV-
infected individuals.
I,, c '
a. High levels of human T lympocyte engraftment. Recent studies in
NOD-SCID mice have demonstrated high levels of splenic engraftment when
human T cell lines (78), spleen cells (20) or 20 x 106 PBMC (28) are injected,
intraperitoneally. These findings are confirmed here in experiments in which
mice were injected with 50 x 106 PBMC from donors with. latent EBV
infection. Close to 50% of spleen cells from reconstituted NOD-SCID mice
expressed the human CD45 surface marker, and most of these also expressed
the T cell marker CD3. In results not presented, spleen cells from more than.
20 reconstituted CB.17-SCID mice were found to contain very few (0% to 5%)
human CD45+ cells. Large numbers of human cells are able to survive and
populate the spleens of PBMC-reconstituted NOD-SCID because this SCID
mouse strain has few intact components of the inate immune response
available to resist the xenogeneic PBMC graft. The comparison made here of
PBMC-reconstitution ,of CB.17- and NOD-SCID mice demonstrates the abilty
of the C. 17-SCID' s inate immunity to prevent the xenograft from becomingwell-established. 
. -
b. Frequency and characterization of LPD.
. N9D-SCID mice were
reconstituted with latently': infected PBMC to determine what effect the large
number of engrafted T cells would have on development of LPD. The results,
of initial reconstitution experiments suggested that these T cells provided
mice with a substantial degree of protection ,againt LPD, since the frequency of
LPD was significantly lower in NOD-SCID mice than in C.B.17-SCID mice. . The
role of CD4 and CD8 T cells in the control of LPD Was clarified in later,
experiments.
The high frequency of LPD in NOD-SCID mice reconstituted withPBMC
from acute 1M donors is consistent with earlier speculation that the acute 1M T
cells undergo apoptosis following transplantation into CB.17-SCID mice, and
hence do not influence the course of LPD. Apoptosis of T cells during acute
viral infection has been shown to be correlated with virus-induced immune
suppression, such as that which can occur with EBV infection (64). It is
possible that apoptosis-induced suppression of T cell immunity in acute IM-
PBMC-reconstituted NOD-SCID mice was responsible for the observed
increase in incidence of LPD compared, the mice receiving latently-infected
PBMC
"'.
, LPD arising in reconstituted NOD-SCID mice was very similar to LPD in
B.17-SCID mice in every characteristic analyzed. The predominant cell
surface phenotype was nearly identical, as was the proportion of tumors with
evidence of EBV replication; the morphology of tumors arising in the two
mouse strains was also identical. While this was not an unexpected 
.finding, it
suggests that similar events lead to the development of tumors in each of
these models.
2. CD4+ and CD8+ T lymphocytes have distinct roles in the outcome 
PBMC reconstitution of NOD-SCID mice.
a. CD8+ T lymphocytes protect PBMC-reconstituted NOD-SCID mice
from LPD. The outcome of in vivo depletion of CD8+ T' cells demonstrate
that CD8+ T cells protect about half of reconstituted NOD-SCID mice from
developing LPD; specific depletion of CD8+ T cells increased the frequency of
LPD from 47% to 100% and decreased survival time. Anti-CD16 antibody had.
little effect on LPD or survival, suggesting thatNK cells do not provide
signficant protection from LPD in this model. However, smce CD16+ cells are
rarely detected in either spleen or peritoneal lavage ce ls of reconstituted mice
it was not possible to confirm that treatment with .anti-CD16 Ab depleted NK
cells from reconstituted mice.
The increase in LPD after treatment with anti-CD8 Ab was due specifically
to .the depletion of CD8+ T cells, rather than to a reduction in the total number
. of engraftedT cells. This Was shown by replenishing the depleted (CD8) celt
population with either purified CD4 + or CD8+ T cells. Only CD8+ cell
replenishment prevented LPD and increased, survival time; replenishment
with CD4+ T cells had no effect on the frequency of LPD and decreased
survival time. The decrease in survival time was apparently due to graft
versus host disease (GVHD) caused by the increased number of CD4+ T cells.
The condition of CD8-depleted mice which were replenished. with CD4 + cells
at autopsies was clinically and histologically consistant with GVHD.
The adoptively transferred purified CD8+ T cells provided a higher level
of protection from LPD than did the CD8+ T cells in the initial PBMC
injection, even though the number of CD8+ cells was the same in each case.
This is apparent when the frequency of. LPD in control mice is compared to
that in mice depleted of CD8+ T cells and then replenished with purified CD8+
p--
"2.'0.
T cells (Table 10 groups E and Ai 90% protected vs. 53%prbtected)). The
purified CD8+ cells were injected into mice with established Tcell grafts, the
CD4+ T cell component of which would produce cytokines capable of
enhanceing the survival and fuction of the CD8+ cells injected at later
timepoints. In contrast, the CD8+ T cells resident in the PBMC injected into
untreated control mice would be subject to some degree of resistance by the
host immune system, and it is likely that fewer of. these cells would survive
long-term. Although the point was. stressec1 earlier that the NOD-SCID mouse
presents fewer obstacles to human PBMC engraftment due to defects in inate
immunity, some proportion of injected cells is presumeably eliminated by
host resistance; this 'is ,evident in the small percentage of mice which do not
become successfully reconstituted, ie: do not produce Hulg.
CD4+ T cells are ,required for T cell engraftment and development
of LPD in NOD-SCID mice. The results of in vivo depletion ofCD4+ Tcells
demonstrate that'CD4+ T cells are 'required for engraftmentof CD8+ T cells in
. the spleen and for,the progression of EBY-infected B cells to LPD. However, it
is apparent that some B cells do engraft in the absence of. CD4 + T cells, since
these mice produced levels of Hulg which, although lower than those of
control mice without LPD, were significant.
The CD4 and CD8 depletion results disagree with those reported by
Yeronese, et al. for the C.B.17-SCID mouse (93). They found that LPD was
prevented when all T cells were removed from PBMC prior to injection, or 
when mice were treated with agents which prevent T cell activation such as
cyclosporin A. However, they also found that removal of either CD4+ or
CD8+ T cells separately did not prevent tumors from forming (84). They
concluded from this that either CD4+ orCD8+ T cells could provide factor(s)
neccessary for EBY+ B cell proliferation ' and progression to LPD. My results
have led me to a very different conclusion, namely, that the only T cells that
are required for development of LPD. are CD4 + T cells. 
A possible explanation for the difference in our findings lies in the
methods used to remove T cell subsets. In the Yeronese .etal. study, CD4 + or
CD8+ T cells were removed from PBMC by immunomagnetic separation
before they were injected into mice; the authors state that residual
contamination with cells bearing the depleted phenotype was 1% or less. It
%",'
seems unlikely that 1% residual CD4+ cells could support B cell proliferation;
however, mice receiving CD4-depleted PBMC in those experiments did take.
more than twice as long to develop LPD, suggesting that the residual CD4+
cells might have expanded in vivo over that period; eventually providing the
level of "help" needed for LPD to progress. The other important difference
between these two studies is the use of different SCID mouse strains. The
results reported here do not, however, provide an obvious solution to why
the two strains would yield different outcomes in these types of experiments. 
A requirement for CD4+ T 'cells for development of EBV-associated LPD
has not been previously reported. However, similar roles for both CD4+' and
CD8+ T cells have been described in a murine model of EBV infection, murine
herpesvirus-68 (MHV":68). MHV-68 shares many molecular and biological
. .
properties with EBV. CD8+ T cells have been shown to be important for
recovery from primary infection of mice with this virus, (15). Acute
lymphoproliferation in the spleen is also Seen iri acute infection, and is
. prevented by depletion of CD4+ T cell
. Like EBV, M 68 establishes a latent
infection in B lymphocytes, and chronically infected mice develop LPD similar
to that seen in immunocompromised EBV-infected patients (82, 83). It is not
yet known what influence CD4+ and CD8+T cells have on development of
LPD in this model, but the results in the NOD SCID mouse would predict that
depletion of CD4 cells wil prevent LPD. Depletion of CD8 cells would 
. predicted to increase the incidence of LPD, which is relatively low (9%) in
MHV-68-infected mice.
3. Comparison of immune reconstitution of C.B.17-SCID and NOD-SCID
mice.
Human PBMC engraftment is enhanced in the NOD-SCID mouse in
comparison to the C.B.17-SCID mouse. It is likely that much of this
enhancement can be attributed to reduced NK cell activity in the NOD-SCID '
strain. Evidence for this includes the finding that depletion of murine NK
. cells results in higher levels of human Ig production in reconstituted C.B.17-
SCID mice (94). However, depletion of NK cell activity from another strain of
SCID mouse, the C57BL/6JSz-scid resulted in only a small increase in PBMC
engraftment compared to untreated mice (20), suggesting that additional factor
also playa significant role. Complement components and macrophage
Jr.
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function, both of which are defective in the NOD-SCID, are potential
contributors to the low level of PBMC engraftment achieved in the C.B.-
SCID mouse.
The experiments in NOD-SCID mice which are described here
demonstrate an important role for 
CDB+ T cells in controllng EBV-inducedLPD. The results do not
, however, distinguish between the several possible
mechanism of control, ie: ditect lysis of EBV-infected cells by CDBt CTL
, or
alter ative mechanism. Healthy individuals who are latenly infected with
, EBV have a relatively large EBV-specific component within the CTL precursorpool of.their PBMC, and it is reason ble to assume that the precursors
maintain this function when transferred into theSCID mouse. 
It is knownthat human B lymphocytes are stimulated to 
spontaneously produce Ig when
inje ted into SCID mice; also, expansion of EBV-infected B cell tumor
precursors occurs without much difficulty in the C.B.17-SCID environment. 
Control of B cell outgro""th by EBV-specific CTL would required these cells to
expand in reponse to EBV antigens. One could therefor determine whether
an EBV-specific CTL-mediated mechanism is responsible for 
tumor control by
measuring an increase in the frequency of EBV 
-specific CTL in PBMC after
residence in the NOD-SCID mouse.
The observation that alloreactive CTL lines protect against LPD in the
C.B. 17-SCID model suggests a second potential mechanism; that is
, secretion o
of one or more cytokines by 
CDB+ T cells that act directly or indirectly on
tumor cells or precursors to control LPD. It might be possible to identify such a
mechanism by neutralizing 
specific cytokines in vivo by administration of an
antibody. Alternatively, one or a combination of candidate cytokines might be
found which could
, when administered . to hu-PBMC-SCID . mice, mimic the
effect of CDB+ T cells in preventing LPD.
PBMC-reconstituted C.B.17-SCID and NOD-SCID mice provide distinct
and complementary models for the study of EBV-
associated LPD and the role
of T cells on its development. In the healthy EBV- infected human host, an
equilbrium is established between virus-induced lymphoproliferation and
the anti-viral immune response. Of the two models
, the reconstituted NOD-
SCID mouse more closely resembles this state of 
equilbrium. As a result
about half of the mice are protected from disease; the fact that a large
i fj
percentage are stil susceptible to tumors poinfs to a relative tilting of the
equilbrium in favor of the EBV-infected cells. The equilibrium is shifted in
favor of protective T cell immunity when additional numbers of CD8+ T cells
are injected into the system, and as a result, tumor incidence decreases.
dramatically. This situation thus models that of the healthy human system
in which the host is protected from EBV-induced LPD,
In the C.B.17-SCID model, the' equilbrium appears to be tilted in favor of 
the virus; following transplantation, the infected human B cells seem to have
a survival advantage over the cells which provide protective immunity
against virus-induced proliferation. The result
. is the outgrowth of tumors in a
majority of C.B. 17-SCID mice; this situation is similar to but more dramatic
than what is thought to be present in the immunosuppressed human host.
The incidence of tumors in human organ transplant recipients
, for example, is
approximately 1%, which is far lower than what is found the C.B.17-SCID
mouse model.
In addition to providing a model for EBV-reJated LPn and
. immunotherapy testing, the hu-PBMC-SCID mouse provides a new model in
which to test pharmacotherapeutiCs and candidate vaccines for viruses which
only infect human or for which there is no alternative animal modeL. These
types. of studies are alread'y being pursued in the ontext of HIV -1 infection (28
59).
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